Physician profile
Shailja Roy
NPI 1508898594
$8,215.89
in general payments reported to CMS, 2019-2025
69 companies · $2,451 in 2025
The $2,451 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $836 · 2020: $192 · 2021: $333 · 2022: $1,027 · 2023: $1,728 · 2024: $1,649 · 2025: $2,451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,779 · Education: $49.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,778.97 |
| Education | $49.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $699.80 | 2019-2025 | |
| Pfizer INC. | $535.02 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $446.43 | 2019-2025 | Enhertu, Lynparza, Calquence |
| Genentech USA, INC. | $383.47 | 2019-2025 | Polivy, Kadcyla, Phesgo |
| Glaxosmithkline, LLC. | $383.25 | 2021-2025 | Jemperli, Zejula, Ojjaara |
| Merck Sharp & Dohme LLC | $374.01 | 2019-2025 | Keytruda, Welireg, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $335.11 | 2021-2025 | Opdualag, Opdivo, Krazati |
| Daiichi Sankyo INC. | $310.08 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Celltrion USA INC. | $259.80 | 2023-2025 | Vegzelma |
| Abbvie INC. | $249.43 | 2019-2025 | Venclexta |
| Astellas Pharma US INC | $247.29 | 2019-2025 | Padcev, Xospata |
| Celgene Corporation | $239.52 | 2019-2025 | Reblozyl |
| Janssen Biotech, INC. | $229.93 | 2019-2025 | Tecvayli, Darzalex, Carvykti |
| Incyte Corporation | $202.39 | 2019-2025 | Jakafi |
| Eisai INC. | $194.94 | 2019-2025 |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $178.74 | 2019-2025 | Trodelvy |
| Exelixis INC. | $146.67 | 2019-2025 | Cabometyx |
| Pharmacyclics LLC, An Abbvie Company | $145.30 | 2020-2023 | Imbruvica, Epkinly |
| Array Biopharma INC | $137.04 | 2022-2025 | Braftovi, Mektovi, Lorbrena |
| Bayer Healthcare Pharmaceuticals INC. | $126.91 | 2019-2024 | |
| Genzyme Corporation | $126.88 | 2019-2025 | |
| Seagen INC. | $122.49 | 2022-2023 | Padcev, Tukysa, Adcetris |
| Lilly USA, LLC | $110.39 | 2019-2025 | Verzenio, Jaypirca |
| Beigene USA, INC. | $103.36 | 2021-2025 | Tevimbra, Brukinsa |
| Spectrum Pharmaceuticals INC. | $99.14 | 2023-2025 | Rolvedon |
| Kite Pharma, INC. | $91.12 | 2019-2025 | Yescarta |
| Sobi, INC | $87.28 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $86.19 | 2019-2024 | Xarelto |
| Stemline Therapeutics INC. | $80.70 | 2023-2025 | Orserdu |
| Apellis Pharmaceuticals, INC. | $79.95 | 2022-2024 | Empaveli |
| Karyopharm Therapeutics INC. | $77.26 | 2023-2024 | Xpovio |
| Pharmacosmos Therapeutics INC. | $72.45 | 2023-2025 | Monoferric |
| Jazz Pharmaceuticals INC. | $72.45 | 2022-2025 | |
| Tempus Ai, INC | $68.70 | 2024-2025 | Xt Cdx |
| Alexion Pharmaceuticals, INC. | $61.87 | 2023-2024 | Ultomiris |
| Invivyd INC | $61.36 | 2025 | Pemgarda |
| Emd Serono, INC. | $60.86 | 2022-2025 | |
| Amgen INC. | $60.68 | 2020-2023 | Nplate, Xgeva, Blincyto |
| Springworks Therapeutics, INC. | $58.75 | 2025 | Ogsiveo, Gomekli |
| Dova Pharmaceuticals | $51.87 | 2019-2020 | |
| Beone Medicines USA, INC. | $51.42 | 2025 | Brukinsa, Tevimbra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.84 | 2020-2025 | Gilotrif |
| Takeda Pharmaceuticals U.S.A., INC. | $46.12 | 2019-2024 | Alunbrig |
| Acrotech Biopharma INC. | $45.49 | 2022-2025 | Ryzneuta |
| Aveo Pharmaceuticals, INC. | $41.13 | 2022 | |
| Secura Bio, INC. | $40.42 | 2019-2023 | Copiktra |
| Regeneron Healthcare Solutions, INC. | $39.80 | 2021-2023 | Libtayo |
| Immunocore Limited | $38.69 | 2025 | Kimmtrak |
| Servier Pharmaceuticals LLC | $35.87 | 2024-2025 | |
| Genmab U.S., INC. | $32.66 | 2024-2025 | Tivdak |
| Puma Biotechnology, INC. | $30.81 | 2024-2025 | |
| Novocure INC. | $27.94 | 2025 | Optune Lua (Novottf-200t) |
| Digestive Care, INC. | $20.75 | 2022 | |
| Adc Therapeutics America, INC. | $20.54 | 2024 | |
| Agios Pharmaceuticals, INC. | $18.86 | 2024 | Pyrukynd |
| Deciphera Pharmaceuticals INC. | $18.41 | 2024 | Qinlock |
| Morphosys, US INC. | $17.83 | 2023 | Monjuvi |
| Geron Corporation | $17.56 | 2024 | Rytelo |
| Cti Biopharma Corp. | $17.38 | 2022 | |
| Aadi Bioscience, INC. | $16.81 | 2023 | Fyarro |
| Helsinn Therapeutics (U.S.), INC. | $15.98 | 2025 | Akynzeo |
| Amneal Pharmaceuticals LLC | $15.96 | 2025 | Alymsys |
| Ipsen Biopharmaceuticals, INC | $15.73 | 2019 | |
| Clovis Oncology, INC. | $14.99 | 2019 | |
| Sumitomo Pharma America, INC. | $13.50 | 2025 | Orgovyx |
| Rigel Pharmaceuticals, INC. | $13.36 | 2024 | Tavalisse, Rezlidhia |
| Fresenius Kabi USA, LLC | $13.32 | 2022 | |
| Advanced Accelerator Applications | $12.85 | 2020 | |
| Tesaro, INC. | $11.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shailja Roy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.